[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-338479-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-338479-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","the-impact-of-pathogenic-brca12-tumor-mutation-status-on-high-grade-serous-epithelial-ovarian-cancer-survival-outcome-amulticenter-study-from-indonesia","The impact of pathogenic BRCA1/2 tumor mutation status on high grade serous epithelial ovarian cancer survival outcome - Amulticenter study from Indonesia","","Evaluation of pathogenic BRCA1 and BRCA2 tumor mutation effects on high-grade serous epithelial ovarian cancer survival in Indonesia. An observational analytic historical cohort study included 68 of 144 patients diagnosed between January 1, 2015 and March 31, 2021 across three Jakarta centers, using next-generation sequencing for BRCA1/2. Survival was compared by mutational status and clinicopathological factors were assessed. Pathogenic mutation carriers showed lower death risk and longer median survival than non-carriers.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/the-impact-of-pathogenic-brca12-tumor-mutation-status-on-high-grade-serous-epithelial-ovarian-cancer-survival-outcome-amulticenter-study-from-indonesia/338479/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/the-impact-of-pathogenic-brca12-tumor-mutation-status-on-high-grade-serous-epithelial-ovarian-cancer-survival-outcome-amulticenter-study-from-indonesia/338479.png","ImageObject",300,407,{"name":42,"@type":43},"Seraphina","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-22","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the study purpose regarding BRCA1/2 mutations?","Question",{"text":63,"@type":64},"To evaluate how pathogenic BRCA1 and BRCA2 tumor mutation status impacts survival outcomes in high-grade serous epithelial ovarian cancer patients in Indonesia.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was the study conducted and what testing was used?",{"text":68,"@type":64},"An observational analytic historical cohort study was performed. Next-generation sequencing was used to test tumor BRCA1 and BRCA2 mutations for comparison of survival outcomes.",{"name":70,"@type":61,"acceptedAnswer":71},"What survival benefit was observed in patients with pathogenic BRCA1/2 mutations?",{"text":72,"@type":64},"The group with pathogenic BRCA1/2 mutations had a significantly lower risk of death and a longer median survival time than the group without those mutations.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},338479,1790491116,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962075114101,"https://ap-avatar.wpscdn.com/avatar/e000253a75eb197efd?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780044092746381165","The impact of pathogenic BRCA1/2 tumor mutation status on high grade serous epithelial ovarian cancer survival outcome: Amulticenter study from Indonesia  \nSAGE Open Medicine Volume 12: 1–13 © The Author(s) 2024 Article reuse guidelines:  \n[sagepub.com/journals-permissions](sagepub.com/journals-permissions)[ ](sagepub.com/journals-permissions)[DOI: 10.1177/20503121241299849](DOI: 10.1177/20503121241299849)[ ](DOI: 10.1177/20503121241299849)[journals.sagepub.com/home/smo](journals.sagepub.com/home/smo)  \nSutrisno Sutrisno 1, Dina Marlina2, Kevin Dominique Tjandraprawira2 and Putri Nadhira Adinda Adriansyah3  \nAbstract  \nIntroduction: Ovarian cancer is still a major health problem in Indonesia. development of breast cancer gene-related personalized medicine to increase the survival outcome of epithelial ovarian cancer patients in Indonesia is expected to be achieved. This research aims to evaluate the impact of pathogenic breast cancer gene 1 and breast cancer gene 2 tumor mutation on high-grade serous epithelial ovarian cancer survival outcome.  \nMethods: This study is an observational analytic study, using a historical cohort study design. A total of 68 from 144 patients diagnosed with International Federation of Gynecology and Obstetrics 2014 stage IIB-IV high-grade serous epithelial ovarian cancer between January 1st, 2015 until March 31st, 2021, at three centers in Jakarta. Next-generation sequencing tumor breast cancer gene 1 and breast cancer gene 2 testing and were included in this cohort historical study. We compared patient’s overall survival outcomes, according to pathogenic breast cancer gene 1 and breast cancer gene 2 tumor mutational status. Clinicopathological characteristic factors that might affect patient’s survival outcomes were also investigated. Results: In the group of individuals with pathogenic breast cancer gene 1 and breast cancer gene 2 tumour mutations, the risk of death was significantly lower by 86%(adjusted RR 0.149; 95% CI: 0.046–0.475; p-value = 0.001), and the median survival time was significantly better (median 46 months; 95% CI: 34.009–57.991; p-value = 0.001) compared to the group without pathogenic breast cancer gene 1 and breast cancer gene 2 tumor mutations (median 23 months; 95% CI: 15.657– 30.343; p-value = 0.001). The multivariate analysis revealed that the presence of a pathogenic breast cancer gene 1 and breast cancer gene 2 tumor mutation is an independent and positive prognostic factor for survival outcome. The adjusted relative risk was 0.149, with a 95% CI of 0.046–0.475, p-value = 0.001.  \nConclusions: In high-grade serous ovarian cancer patients, the pathogenic breast cancer gene 1 and breast cancer gene 2 tumor mutations group have a better prognosis with longer survival outcomes than those without pathogenic breast cancer gene 1 and breast cancer gene 2 tumor mutations.  \nKeywords  \nGenital neoplasms, ovarian neoplasms, high-grade serous epithelial ovarian carcinoma, pathogenic BRCA1/2 tumor mutation, clinical outcome, survival outcome  \nDate received: 2 June 2024; accepted: 22 October 2024  \n1 Division of Gynecologic Oncology, Faculty of Medicine, Department of Obstetrics and Gynecology, Indonesia University, Dr. Cipto Mangunkusumo National Central Referral Hospital, Central Jakarta, Indonesia  \n2Faculty of Medicine, Department of Obstetrics and Gynecology, Universitas Padjadjaran—Dr. Hasan Sadikin General Hospital, Bandung, Indonesia  \n3Faculty of Medicine, Padjadjaran University, Bandung, West Java, Indonesia  \nCorresponding author:  \nSutrisno Sutrisno, Division of Gynecologic Oncology, Faculty of Medicine, Department of Obstetrics and Gynecology, Indonesia University, Dr. Cipto Mangunkusumo National Central Referral Hospital, Jl. Pangeran Diponegoro No.71, Central Jakarta 53146, Indonesia.  \nEmail: [sutrisno0683@gmail.com](sutrisno0683@gmail.com)  \nCreative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-Non","cbCaip7xuvLlI8Zn","https://ap.wps.com/l/cbCaip7xuvLlI8Zn","pdf",805356,13,"English","# Introduction\n## Ovarian cancer burden in Indonesia and globally\n# Methods\n## Study design and patient cohort\n## BRCA1/2 testing and outcome measures\n# Results\n## Survival and risk of death by mutational status\n## Multivariate prognostic findings\n# Conclusions","[{\"question\":\"What was the study purpose regarding BRCA1/2 mutations?\",\"answer\":\"To evaluate how pathogenic BRCA1 and BRCA2 tumor mutation status impacts survival outcomes in high-grade serous epithelial ovarian cancer patients in Indonesia.\"},{\"question\":\"How was the study conducted and what testing was used?\",\"answer\":\"An observational analytic historical cohort study was performed. Next-generation sequencing was used to test tumor BRCA1 and BRCA2 mutations for comparison of survival outcomes.\"},{\"question\":\"What survival benefit was observed in patients with pathogenic BRCA1/2 mutations?\",\"answer\":\"The group with pathogenic BRCA1/2 mutations had a significantly lower risk of death and a longer median survival time than the group without those mutations.\"}]","The impact of pathogenic BRCA1/2 tumor mutation status on high grade serous epithelial ovarian cancer survival outcome - Amulticenter study from Indonesia | PDF",1790023788,33,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/918cd9c58f00fe564c63dafee71735b8.webp",983,1272,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/08a822dc7a1074697c9b4252cd180e14.webp",982,1270,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e14b970582a0a19c67986ad3c21efe9f.webp",981,1269,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a20909e1db8471f0ae500d9e1e854c76.webp",980,1268]